-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cellarity is a life science company founded by Flagship Pioneering, dedicated to the development of a new drug discovery method for cells.
Recently, Cellarity announced that it has received USD 123 million in Series B financing.
In addition to Flagship Pioneering, investors in this round of financing include BlackRock, The Baupost Group, Banque Pictet and eight other investors.
Cellarity was established in 2017 and is headquartered in Cambridge, USA.
It is a company dedicated to the development of new drugs targeting cells.
Its new drug discovery method is based on a computational model of cell behavior, which can provide a more comprehensive understanding of system and network biology, thereby discovering drugs that target cell behavior for a variety of diseases.
Reference materials:
[1] Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target.
Retrieved 2021-02-25, from https://www.
prnewswire.
com/news-releases/cellarity-raises-123-million-in-series-b-funding-to-pioneer-a-new-approach-to-drug-discovery-treating-disease-at-the-level- of-the-cell-as-opposed-to-a-single-molecular-target-301235332.
html
Cellarity is a life science company founded by Flagship Pioneering, dedicated to the development of a new drug discovery method for cells.
Recently, Cellarity announced that it has received USD 123 million in Series B financing.
In addition to Flagship Pioneering, investors in this round of financing include BlackRock, The Baupost Group, Banque Pictet and eight other investors.
Cellarity was established in 2017 and is headquartered in Cambridge, USA.
It is a company dedicated to the development of new drugs targeting cells.
Its new drug discovery method is based on a computational model of cell behavior, which can provide a more comprehensive understanding of system and network biology, thereby discovering drugs that target cell behavior for a variety of diseases.
Reference materials:
[1] Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target.
Retrieved 2021-02-25, from https://www.
prnewswire.
com/news-releases/cellarity-raises-123-million-in-series-b-funding-to-pioneer-a-new-approach-to-drug-discovery-treating-disease-at-the-level- of-the-cell-as-opposed-to-a-single-molecular-target-301235332.
html
![2-(Hydroxymethyl)benzo[b]thiophene](https://file.echemi.com/fileManage/upload/cas/593/e79a972f-b55d-4dc1-9113-841c417e0a89.png)
